Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency (Q37974585)

26 August 2017

Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency (English)

1 reference

26 August 2017

Jenny A Visser

1

1 reference

26 August 2017

Izaäk Schipper

series ordinal

2

1 reference

26 August 2017

Joop S E Laven

series ordinal

3

1 reference

26 August 2017

Axel P N Themmen

series ordinal

4

1 reference

26 August 2017

10 January 2012

1 reference

Nature Reviews Endocrinology

26 August 2017

1 reference

26 August 2017

8

1 reference

26 August 2017

331-341

1 reference

26 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2011.224

26 August 2017

0 references

cites work

Premature ovarian failure

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Primary ovarian insufficiency: a more accurate term for premature ovarian failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Clinical practice. Primary ovarian insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Primary ovarian insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

The variability of female reproductive ageing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Premature ovarian failure: an update.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Genes involved in human premature ovarian failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

The biology of infertility: research advances and clinical challenges

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotropic ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Brief report: testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Arrest of follicular development in a patient with 17 alpha-hydroxylase deficiency: folliculogenesis in association with a lack of estrogen synthesis in the ovaries

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

An update: spontaneous premature ovarian failure is not an early menopause

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A prospective evaluation of antral follicle function in women with 46,XX spontaneous primary ovarian insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Increased frequency of occult fragile X-associated primary ovarian insufficiency in infertile women with evidence of impaired ovarian function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Premature ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Recent developments in identifying genetic determinants of premature ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Genome-wide association study in premature ovarian failure patients suggests ADAMTS19 as a possible candidate gene.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Premature ovarian failure and gene polymorphisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A genome-wide linkage scan in a Dutch family identifies a premature ovarian failure susceptibility locus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Genome-wide association study and premature ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Premature ovarian failure in the fragile X syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Fragile X premutation is a significant risk factor for premature ovarian failure: the International Collaborative POF in Fragile X study--preliminary data

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Fragile X premutation screening in women with premature ovarian failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Characterization of idiopathic premature ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Childhood cancer survival in Europe and the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Childhood Cancer Survival Trends in Europe: A EUROCARE Working Group Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Long-Term Follow-Up of Survivors of Childhood Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Long-term endocrine side effects of childhood Hodgkin's lymphoma treatment: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Premature ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Regulation of ovarian function: the role of anti-Müllerian hormone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Bone morphogenetic protein-6 stimulates gene expression of follicle-stimulating hormone receptor, inhibin/activin beta subunits, and anti-Müllerian hormone in human granulosa cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Oocyte regulation of anti-Müllerian hormone expression in granulosa cells during ovarian follicle development in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone remains highly expressed in human cumulus cells during the final stages of folliculogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Evidence for a role for anti-Mullerian hormone in the suppression of follicle activation in mouse ovaries and bovine ovarian cortex grafted beneath the chick chorioallantoic membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A polymorphism in the AMH type II receptor gene is associated with age at menopause in interaction with parity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Increased oocyte degeneration and follicular atresia during the estrous cycle in anti-Müllerian hormone null mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Müllerian-inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Estradiol and regulation of anti-Müllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicles' fluid.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Developmental and endocrine aspects of normal ovarian aging.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Antral follicle counts by transvaginal ultrasonography are related to age in women with proven natural fertility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Time course of the serum gonadotropin surge, inhibins, and anti-Müllerian hormone in normal newborn males during the first month of life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone levels in serum from human foetuses and children: pattern and clinical interest.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum Levels of Anti-Müllerian Hormone as a Marker of Ovarian Function in 926 Healthy Females from Birth to Adulthood and in 172 Turner Syndrome Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-müllerian hormone is a promising predictor for the occurrence of the menopausal transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Antimüllerian hormone serum levels: a putative marker for ovarian aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum anti-Müllerian hormone levels: a novel measure of ovarian reserve

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Correlation of ovarian reserve tests with histologically determined primordial follicle number

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A validated model of serum anti-müllerian hormone from conception to menopause

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

External validation of nomogram for the decline in serum anti-Müllerian hormone in women: a population study of 15,834 infertility patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum anti-Mullerian hormone throughout the human menstrual cycle.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Changes in serum antimüllerian hormone levels across the ovulatory menstrual cycle in late reproductive age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Clinical uses of anti-Müllerian hormone assays: pitfalls and promises

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Relationship of serum antimüllerian hormone concentration to age at menopause

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Predicting age at menopause from serum antimüllerian hormone concentration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A single test of antimullerian hormone in late reproductive-aged women is a good predictor of menopause

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum anti-Müllerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles--implications for individualization of therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Relevance of anti-Mullerian hormone measurement in a routine IVF program.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Antimüllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum anti-müllerian hormone levels in women with secondary amenorrhea

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Serum anti-Müllerian hormone expression in women with premature ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Association of FMR1 repeat size with ovarian dysfunction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Mullerian hormone indicates early ovarian decline in fragile X mental retardation (FMR1) premutation carriers: a preliminary study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Correlation of triple repeats on the FMR1 (fragile X) gene to ovarian reserve: a new infertility test?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A pilot study of premature ovarian senescence: I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Intermediate sized CGG repeats are not a common cause of idiopathic premature ovarian failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Turner's syndrome and fertility: current status and possible putative prospects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

X chromosome and ovarian failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Markers of ovarian reserve in young girls with Turner's syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

High serum inhibin concentration discriminates autoimmune oophoritis from other forms of primary ovarian insufficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Primary ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A pilot study of premature ovarian senescence: II. Different genotype and phenotype for genetic and autoimmune etiologies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

GnRH analogs do not protect ovaries from chemotherapy-induced ultrastructural injury in Hodgkin's lymphoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Twins born after transplantation of ovarian cortical tissue and oocyte vitrification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Monitoring the ovaries after autotransplantation of cryopreserved ovarian tissue: endocrine studies, in vitro fertilization cycles, and live birth.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Limited value of ovarian function markers following orthotopic transplantation of ovarian tissue after gonadotoxic treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Autotransplantation of cryopreserved ovarian tissue in 12 women with chemotherapy-induced premature ovarian failure: the Danish experience.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Ovarian function after removal of an entire ovary for cryopreservation of pieces of cortex prior to gonadotoxic treatment: a follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Müllerian hormone, inhibin B and ovarian ultrasound

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Predictors of ovarian reserve in young women with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Pretreatment serum anti-müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Regulation of ovarian follicle atresia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

TGF-beta signal transduction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

Transcriptional control by the TGF-beta/Smad signaling system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

AMH signaling: from receptor to target gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the estrous cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.224

The anti-Müllerian hormone

31 March 2020

1 reference

12 December 2020

Mullerian inhibiting substance: a gonadal hormone with multiple functions

1 reference

12 December 2020

Mullerian inhibiting substance in humans: normal levels from infancy to adulthood.

1 reference

12 December 2020

Primary ovarian insufficiency: autoimmune causes

1 reference

12 December 2020

Recommendations for the diagnosis and management of Turner syndrome

1 reference

12 December 2020

Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy

1 reference

12 December 2020

A syndrome of female pseudohermaphrodism, hypergonadotropic hypogonadism, and multicystic ovaries associated with missense mutations in the gene encoding aromatase (P450arom).

1 reference

12 December 2020

Anti-müllerian hormone: the Jost factor.

1 reference

12 December 2020

Incidence of premature ovarian failure.

1 reference

12 December 2020

Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure

1 reference

12 December 2020

Initial and cyclic recruitment of ovarian follicles

1 reference

12 December 2020

Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells.

1 reference

12 December 2020

Subfertility in children and young people treated for solid and haematological malignancies

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2011.224

1 reference

26 August 2017

1 reference